Resverlogix's BET Protein Inhibitor RVX-208 Meets Primary Endpoint in SUSTAIN Clinical Trial in Patients With High Risk Cardiovascular Disease

Resverlogix's BET Protein Inhibitor RVX-208 Meets Primary Endpoint in SUSTAIN Clinical Trial in Patients With High Risk Cardiovascular Disease PR Newswire MUNICH and CALGARY, Alberta, August 28, 2012 MUNICH and CALGARY, Alberta, August 28, 2012 /PRNewswire/ -- -- Significant Increase in Functional HDL Persisted Throughout the 24-week Study Period -- -- Results from ASSURE Study Expected H1 2013, Using IVUS to Measure Regression of Atherosclerotic Plaque -- TSX Exchange Symbol: RVX Resverlogix Corp. (TSX: RVX) today announced that the BET protein inhibitor RVX-208 significantly increased HDL-C (p=0.001), the primary endpoint of the SUSTAIN trial, a phase 2b clinical study. SUSTAIN also successfully met secondary endpoints, showed increases in levels of Apo-AI (p=0.002) and large HDL particles (p=0.02), both believed to be important factors in enhancing reverse cholesterol transport activity. The SUSTAIN trial also showed that increases in alanine aminotransferase (ALT) reported in previous trials were infrequent and transient with no new increases observed beyond week 12 of the 24-week trial. The SUSTAIN trial was directed by a clinical steering committee chaired by Dr. Steven Nissen with Dr. Stephen Nicholls serving as Principal Investigator. The committee has approved release of topline findings pending submission of full trial results for publication in a peer-reviewed medical journal.